Last reviewed · How we verify
NCT04095195: IRFARPC
Registry of Subjects at Risk of Pancreatic Cancer
trial testing MRCP in Familial Pancreatic Cancer in 1,000 participants. Currently enrolling.
20 August 2044
Quick facts
| Lead sponsor | Associazione Italiana per lo Studio del Pancreas |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 20 August 2019 |
| Primary completion | 20 August 2044 |
| Estimated completion | 20 September 2045 |
| Sites | 4 locations across Italy |
Drugs / interventions tested
- MRCP
- Endoultrasonography
Conditions studied
- Familial Pancreatic Cancer — all drugs for Familial Pancreatic Cancer →
- BRCA1 Mutation — all drugs for BRCA1 Mutation →
- BRCA2 Mutation — all drugs for BRCA2 Mutation →
- Lynch Syndrome — all drugs for Lynch Syndrome →
Sponsor
Associazione Italiana per lo Studio del Pancreas — full company profile →
Who can join
Adults 18 to 80, any sex, with Familial Pancreatic Cancer or BRCA1 Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer.
Paiella S, Capurso G, Carrara S, Secchettin E, et al · · 2024 · cited 12× · PMID 37787643 · DOI 10.14309/ajg.0000000000002546
Verify or expand the search:
- PubMed search for NCT04095195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Familial Pancreatic Cancer
Currently open trials in the same condition.
- NCT04743479 — Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI) · recruiting
- NCT04247503 — Cohort Study of Pancreatic Cancer Risk · active not recruiting
- NCT00835133 — Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Mel · active not recruiting
Other Associazione Italiana per lo Studio del Pancreas trials
Trials by the same sponsor.
- NCT05724992 — Familial Pancreatic Cancer PROPHilation Program in Italy · NA · recruiting
- NCT05733130 — Italian Registry Chronic Pancreatitis · recruiting
- NCT04793932 — Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) · Phase 3 · active not recruiting
- NCT06381362 — Italian Registry of Minimally Invasive Pancreatic Surgery · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04095195 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Associazione Italiana per lo Studio del Pancreas
- Last refreshed: 13 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04095195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing